Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 269-273

  Middleton, G W ^a   Smith, I E ^a   O'Brien, M E R ^a   Norton, A ^a   Hickish, T ^a   Priest, K ^a   Spencer, L ^a   Ashley, S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemotherapy; Mesothelioma; Symptom relief

Indexed keywords

CISPLATIN; MITOMYCIN C; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; PRIORITY JOURNAL;

EID: 0031976978     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008236010868     Document Type: Article

References (24)

1. Krarup Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 1991; 28: 319-30.
2. Ong FT, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 1996: 14: 1007 17.
3. Solheim OP, Saeter G, Finnanger AM et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956 60.
4. Vogclzang NJ, Weissman LB, Herndon JE et al. Trimetrexate in malignant mesothelioma: A CALGB phase II study. J Clin Oncol 1994: 12: 1436-42.
5. Belani CP, Herndon J, Vogelzang NJ et al. Edatrexate for malignant mesothelioma: A phase 11 study of the Cancer and Leukaemia Group B, 913. Proc Am Soc Clin Oncol 1994; 13: 329 (Abstr 1087).
6. Alberts AS, Falkson G, Zyl LV. Malignant pleural mesothelioma: Phase II pilot study of Ifosfamide and mesna. J Natl Cancer Inst 1988; 80: 698-700.
7. Zidar BL, Melch B, Balcerzak SP et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study. Cancer 1992; 70: 2547-51.
8. Falkson G, Hunt M, Borden EC et al. An extended phase II trial of Ifosfamide plus mesna in malignant mesothelioma. Invest New-Drugs 1992; 10: 337-43.
9. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin-C, vinblastine and cisplalin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71: 366 70.
10. Chahinian AP, Antman K, Goutsou M et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukaemia Group B. J Clin Oncol 1993; 11: 1559-65.
11. Chahinian AP, Szrafer L, Malawi S. Comparative activity of three platinum analogues against human malignant mesothelioma xenografts in nude mice. Proc Am Assoc Cancer Res 1985; 26: 261 (Abstr).
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma (from the International Mesothelioma Interest Group). Chest 1995; 108: 1122 8.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
15. Kaplan EL, Meier P. Non parametric estimation from incomplete estimation. J Am Stat Assoc 1958; 53: 457-81.
16. World Health Organisation. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
17. Butchart EG, Ashcroft T, Barnsley WC et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976; 31: 15-24.
18. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
19. Rusch VW. Trials in malignant mesothelioma. LCSG 851 and 882. Chest 1994; 106: 359 62.
20. Sugarbaker DJ, Strauss GM, Lynch TJ et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993; 11: 1172-8.
21. Law MR, Gregor A, Hudson ME et al. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984; 39: 255-9.
22. Gordon W, Antman K, Breenberger et al. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982; 8: 19.
23. Rusch V, Niedzwiecki D, Pow Yet al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies. J Clin Oncol 1992; 10: 1001-6.
24. Markman M, Cleary S, King M et al. Cisplatin and cytarabine administered intrapleurally as treatment for malignant pleural effusions. Med Pediatr Oncol 1985; 13: 191-3.